PT-141 (Bremelanotide)
FDA-approved therapy for sexual desire through central nervous system activation.
From $199/mo
How It Works
PT-141 is a cyclic lactam heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) that acts as an agonist at melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the central nervous system. MC4R activation in the medial preoptic area and paraventricular nucleus of the hypothalamus - brain regions critical for sexual function - triggers downstream signaling through oxytocin and dopamine pathways that facilitate sexual desire and arousal. The melanocortin system is a key integrator of multiple inputs affecting sexual motivation, including hormonal, emotional, and sensory signals. PT-141 essentially lowers the activation threshold for sexual arousal at the neural circuit level.
Key Benefits
Clinical Research
The RECONNECT trial program comprised two Phase 3, randomized, double-blind, placebo-controlled studies in premenopausal women with HSDD. RECONNECT-1 (n=684) and RECONNECT-2 (n=656) demonstrated that 1.75 mg subcutaneous PT-141 produced statistically significant increases in sexual desire (measured by the Female Sexual Function Index desire domain) and significant reductions in distress related to low sexual desire (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm). Approximately 25% of treated patients achieved a clinically meaningful response vs 17% on placebo. Earlier Phase 2 studies in men with erectile dysfunction showed improved erection quality in patients who did not respond to sildenafil, suggesting efficacy through a complementary mechanism. Safety data across trials showed the most common adverse event was nausea (40%), which was typically transient and mild to moderate.
Dosage & Administration
Dosage
The FDA-approved dose is 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Do not administer more than one dose within 24 hours or more than 8 doses per month. Some compounding protocols use doses ranging from 0.5 mg to 2.0 mg based on individual response and tolerance. Starting at a lower dose (0.5-1.0 mg) and titrating up can help minimize nausea. Your GetPepWell physician will establish an individualized dosing protocol.
Administration
Administered as a subcutaneous injection in the abdomen or thigh at least 45 minutes before anticipated sexual activity. Use a 29-31 gauge insulin syringe. The onset of effects typically occurs within 30-60 minutes and may last 6-12 hours, though individual experiences vary. Anti-nausea medication (such as ondansetron) may be prescribed alongside PT-141 for the first few doses until tolerance develops. Do not consume excessive alcohol before or after administration, as this may increase nausea and reduce efficacy.
Side Effects
- Nausea (most common - affects ~40%, usually transient and decreases with subsequent doses)
- Flushing (skin warmth and redness)
- Headache
- Injection site reactions
- Transient increase in blood pressure (typically 2-6 mmHg)
- Nasal congestion
Contra-indications
- Uncontrolled hypertension or cardiovascular disease
- Known hypersensitivity to bremelanotide or any excipients
- Concurrent use of naltrexone-containing products (blocks melanocortin pathway)
- Pregnancy or breastfeeding
- History of myocardial infarction or stroke within the past 6 months
- Hepatic impairment (reduced clearance)
Drug Interactions
- Naltrexone - significantly reduces PT-141 efficacy by blocking melanocortin signaling; contraindicated
- Antihypertensives - PT-141 may transiently raise blood pressure; monitor closely
- PDE5 inhibitors (sildenafil, tadalafil) - combination has not been formally studied; use with caution
- Alcohol - may worsen nausea and reduce efficacy
Storage Info
Store lyophilized powder refrigerated at 36-46 degrees F (2-8 degrees C). After reconstitution, store refrigerated and use within 30 days. Pre-filled syringes should be stored refrigerated. Protect from light. Do not freeze. Allow the solution to reach room temperature for 5-10 minutes before injection to reduce discomfort.
PT-141 (Bremelanotide) FAQ
Find answers to the most common questions about this treatment.
Related Products
Interested in PT-141 (Bremelanotide)?
Schedule a consultation with a licensed physician to see if this treatment is right for you.